An observational study in Acute Coronary Syndrome, STEMI and Coronary Occlusion, sponsored by Powerful Medical. Active, not recruiting at 9 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Powerful Medical · Observational
AI ECG TIMI is an investigator-initiated, international, and multicenter registry of acute coronary syndrome patients aimed to identify electrocardiographic findings detected by an AI model predicting coronary blood flow alteration. The aim of the study is to identify electrocardiographic findings detected by an automated artificial intelligence (AI) model that can predict coronary blood flow alteration as assessed by the TIMI grade flow at the very moment of the invasive coronary angiography in patients with acute coronary syndromes.
1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.
This study's planned enrollment of 800 is above the median of 500 across 561 observational studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →Powerful Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults (18 or older) with acute coronary syndrome undergoing clinically indicated invasive coronary angiography, with a standard 12-lead ECG performed at invasive coronary angiogram before percutaneous coronary intervention (maximum within 15 min before vascular access)
Exclusion Criteria:
Diagnostic Accuracy of the AI-ECG TIMI AI Model
The primary endpoint is the AI-ECG TIMI model's ability to identify patients with actively occluded (TIMI 0-1) at the time of invasive coronary angiography using only single-standard 12-lead ECGs assessed by accuracy, sensitivity, specificity, positive, negative predictive values and F1 scores.
Time frame: Index hospitalization (assessed up to 5 days)
Subgroup Performance
AI-ECG TIMI AI Model's performance across subgroups 1. Demographic 2. Risk factors \& co-morbidities 3. Electrocardiographic 4. Culprit artery territory
Time frame: Index hospitalization (assessed up to 5 days)
Correlate established definitions of occlusion myocardial infarction (OMI) to myocardial perfusion status
2\. OMI definitions using routine angiographic and laboratory parameters will be correlated to abnormal myocardial perfusion using correlation coefficients.
Time frame: Index hospitalization (assessed up to 5 days)
ECG prediction of mechanical reperfusion
a. Correlation of AI-ECG TIMI model's raw numeric predictions (between 0 and 1) with myocardial perfusion grading post PCI.
Time frame: Index hospitalization (assessed up to 5 days)
Assessment of expert ECG interpretation blinded to all clinical information
1. Accuracy, sensitivity, specificity, positive and negative predictive value of expert interpretation of active OMI, reperfused OMI and entirety of OMI 2. Inter-rater variability of expert interpretation of active OMI, reperfused OMI and entirety of OMI.
Time frame: Index hospitalization (assessed up to 5 days)
STEMI-equivalent ECG patterns
a. Prevalence of STEMI equivalent ECG patterns and their correlation to TIMI flow grade at angiography.
Time frame: Index hospitalization (assessed up to 5 days)
Subgroup analysis of NSTEMI-OMI patients
9\. NSTEMI-OMI stratified according to immediate (\<2h) vs. SoC (\>2h) invasive management, median: i. Peak troponin (maximum rise before fall) ii. Median LVEF at discharge iii. Length of hospital stay iv. Length of cardiac care unit (CCU) or intensive care unit (ICU) stay v. Presence of life-threatening arrhythmias
Time frame: Index hospitalization (assessed up to 5 days)
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Powerful Medical